<DOC>
	<DOCNO>NCT02702076</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled trial evaluate efficacy continuous apomorphine infusion compare placebo PD patient visual hallucination , inadequately control clozapine cholinesterase inhibitor .</brief_summary>
	<brief_title>Apomorphine Parkinson 's Disease Patients With Visual Hallucinations : RCT</brief_title>
	<detailed_description>Introduction Visual hallucination occur frequently Parkinson 's disease ( PD ) . The prevalence visual hallucination range 22 38 % ( Fénelon Alves , 2010 ) , increase long-term follow-up 60 % ( Goetz et al. , 2010 ) . Risk factor visual hallucination age ( Fénelon Alves , 2010 ; Gallagher et al. , 2011 ) , disease duration ( Fénelon Alves , 2010 ; Gallagher et al. , 2011 ) cognitive impairment ( Gallagher et al. , 2011 ) . The treatment visual hallucination cumbersome option limit . Only clozapine proven efficacious without deteriorate motor symptom PD . Instead oral dopamine agonist rotigotine , continuous infusion apomorphine well-tolerated PD patient cognitive impairment and/or visual hallucination ( Borgemeester et al. , 2016 ; Garcia-Ruiz et al. , 2008 ; Martin-Martinez et al. , 2011 ; 2015 ) . Even beneficial effect apomorphine visual hallucination suggest ( van Laar et al. , 2010 ; Ellis et al. , 1997 ) , however lack randomize controlled trial . The purpose randomise , double-blind , placebo-controlled trial evaluate efficacy continuous apomorphine infusion compare placebo PD patient visual hallucination , inadequately control clozapine cholinesterase inhibitor .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Hallucinations</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>Female male subject age ≥30 ; Diagnosis establish PD , define Movement Disorders Society PD criterion ( Postuma et al. , 2015 ) ; Presence visual severe hallucination define 3 time week ( van Laar et al. , 2010 ) ; Visual hallucination must develop PD diagnosis ; Visual hallucination must optimally treat reduction dopamine agonists possible , prescription clozapine and/or cholinesterase inhibitor need ; Female subject must complaint highly effective contraceptive method ( oral hormonal contraception alone consider highly effective must use combination barrier method ) study , sexually active ; Subjects able capable adhere protocol , visit schedule , medication intake accord judgement investigator . Symptomatic , clinically relevant medically uncontrolled orthostatic hypotension ; Patients prolong QT interval correct heart rate accord Bazett 's formula ( QTc ) &gt; 450 m male &gt; 470 ms female screening , history long QT syndrome ; PD medication change ( i.e. , dopamineagonists , amantadine , monoamine oxidase ( MAO ) B inhibitor , anticholinergic cholinesterase inhibitor ) last month prior initiation ( van Laar et al. , 2010 ) ; Active psychosis history significant psychosis ; Any medical condition likely interfere adequate participation study include e.g . current diagnosis unstable epilepsy , clinically relevant cardiac dysfunction and/or myocardial infarction stroke within last 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Apomorphine</keyword>
</DOC>